GM 2505
Alternative Names: GM-2505Latest Information Update: 22 Mar 2024
At a glance
- Originator Gilgamesh Pharmaceuticals
- Class Antidepressants; Small molecules
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Major depressive disorder
Most Recent Events
- 31 Jan 2024 Phase-II clinical trials in Major depressive disorder in USA (IV) (NCT06236880)
- 30 Nov 2023 Gilgamesh Pharmaceuticals plans a phase IIa trial for major depressive disorder in Q1 of 2024
- 30 Nov 2023 Pharmacokinetics and pharmacodynamics data from a phase I trial released by Gilgamesh Pharmaceuticals